NICE recommends ixekizumab for persistent severe plaque psoriasis

Click for article

The National Institute for Health and Care Excellence (NICE), in its final draft guidance issued this week, has recommended ixekizumab, an antibody that inhibits interleukin-17A, as an option for treating adults with severe plaque psoriasis that doesn’t respond to standard therapies.

Advertisements

0 Responses to “NICE recommends ixekizumab for persistent severe plaque psoriasis”



  1. Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s




Links to other pages

Blog Stats

  • 26,640 hits

Enter your email address to follow this blog and receive notifications of new posts by email.

Search by category

Archive of previous posts


%d bloggers like this: